latest news releases from the newsroom
Ceragenix and Megapharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
DENVER, Jul 27, 2009 -- Ceragenix Pharmaceuticals, Inc.("Ceragenix"), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with Megapharm Ltd., an Israeli company, ("Megapharm"), to commercialize EpiCeram(R), a topical cream for treating atopic dermatitis and other dry skin conditions in Israel and the Palestinian territories (the "Territory"). The Agreement grants Megapharm exclusivity in the Territory for the distribution and marketing of EpiCeram(R) while Ceragenix will be responsible for the manufacturing and supply of the product. Megapharm is also responsible for obtaining regulatory clearance to market EpiCeram(R) in the Territory. Financial terms were not disclosed.
Gilat Satellite Networks Ltd.
Argentina's Servicio Satelital Selects Gilat's SkyEdge II Broadband Satellite Network
PETAH TIKVA, Israel, July 27, 2009 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq:GILT) today announced it will provide Servicio Satelital S.A. with a Gilat SkyEdge II satellite communications network to enable broadband Internet connectivity at hundreds of sites nationwide. The sites will include schools, oil & gas firms and retail lottery locations. The new network will also be used to provide communication services for telecommunications operators and ISPs that need satellite connectivity in the region. Servicio Satelital is Argentina's largest provider of satellite-based broadband services.
Taro Pharmaceutical Industries Ltd.
Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement
HAWTHORNE, N.Y, July 27, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) said today that it has filed a lawsuit against Synerx Pharma, LLC, DPT Laboratories, Ltd. and Karalex Pharma, LLC (a subsidiary of Eagle Pharmaceuticals, Inc.) in the United States District Court for New Jersey for infringement of its United States Patent No. 7,560,445 covering its Ovide(r) (malathion) Lotion, 0.5%. The suit alleges that the defendants' generic malathion lotion, 0.5%, infringes on Taro's patent, either directly or indirectly. Taro seeks injunctive relief as well as damages for infringement of its patent by the defendants.
ICC Worldwide, Inc.
ICC Simplifies Capital Structure With Reduction of Fully Diluted Shares and Reorganization of Debt
CORONA DEL MAR, Calif., July 27, 2009 (GLOBE NEWSWIRE) -- ICC Worldwide, Inc. (OTCBB:ICCW) today announced that a comprehensive agreement had been reached with four of the firm's principal financing sources to consolidate a total of ten existing promissory notes, each with varying terms and conditions, into four new superseding notes with a much more consistent set of terms. The new notes all carry a 10% interest rate and mature on June 30, 2013. The effect of this consolidation not only reduces the number of notes outstanding to a single note per lender, it also simplifies the company's capital structure and reduces the number of fully diluted common shares.
Taro Pharmaceutical Industries Ltd.
Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets (OTC) ANDA
HAWTHORNE, N.Y., July 27, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg ("Cetirizine Tablets"). The product will be marketed by Taro's U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.
StellarOne Corporation Reports Second Quarter Results
CHARLOTTESVILLE, Va., July 27, 2009 (GLOBE NEWSWIRE) -- StellarOne Corporation (Nasdaq:STEL) (StellarOne) today reported a second quarter 2009 loss of $326 thousand and a net loss available to common shareholders of $785 thousand, or $0.03 per diluted common share. Those results compare to net income of $6.1 million, or diluted earnings per share of $0.27 during the same period in the prior year, and a net loss to common shareholders of $298 thousand or $0.01 per diluted common share recognized for the first quarter of 2009.
Dutch Ministry of Defence Focuses On Data in Key Modernization Project
NIEUWEGEIN, Netherlands, July 27, 2009 (GLOBE NEWSWIRE) -- Informatica Corporation (Nasdaq:INFA), a leading independent provider of data integration software and services, today announced that the Ministry of Defence has selected the Informatica Data Integration Platform to enable the integration of 70 legacy IT systems into a centralized SAP-based ERP environment.